FindMyKOL

Imran Memon, MD

Basic profile

Texas Health Harris Methodist Hospital Fort Worth

ORCIDNone on fileNPIOn fileSign in to see identifiers
✓ Itemized record
RegionFort Worth, TX · South CentralSpecialtyNephrologyFocusNephrology
Active KOLFindMyKOL type: RegionalLatest publicationSee ScholarshipOnline presenceNot yet checkedPayments2021 onwardNIH fundingNot yet indexedWhy? →

Imran Memon is a Nephrology physician affiliated with Texas Health Harris Methodist Hospital Fort Worth. OpenAlex indexes 21 publications with 810 citations (h-index 9).

Overview

Scholarship

indexed output and impact (OpenAlex)
21publications

Publications indexed by OpenAlex. Counts exclude supporting files.

810citations

Citations across these publications.

9h-index

H-index from these publications.

Clinical & industry

trials, payments and federal funding
25companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓

Industry payments

25 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

  • Amgen Inc.
    Program year202517 payments
    $268
  • Calliditas Therapeutics US Inc.
    Program year20253 payments
    $69
  • Merck Sharp & Dohme LLC
    Program year20253 payments
    $65
All 46 payment records: search, sort and filter.Explore →

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.

Medicare prescribing footprint (2023)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cardiovascular

    50.4%
    Calcium channel blocker9.8%
    Amlodipine Besylate57%Nifedipine Er44%
    Part D≥64 patients
    Statin8.5%
    Pravastatin Sodium58%Atorvastatin Calcium29%Simvastatin7%Rosuvastatin Calcium6%
    Part D<11 patients

    + 15 more classes in this area

  • Metabolism & gastrointestinal

    27.1%
    Corticosteroid8.7%
    Prednisone100%
    Part D≥58 patients
    Proton pump inhibitor4.5%
    Pantoprazole Sodium100%
    Part D≥31 patients

    + 9 more classes in this area

  • Musculoskeletal

    4.9%
    Xanthine oxidase inhibitor4.9%
    Allopurinol100%
    Part D≥51 patients
Where care is delivered (Part B)67.4% facility · 32.6% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet. Reviewed account links and congress post links can appear separately. Absence of a section means “not yet looked,” never “none found.”